Medpace (MEDP) Q1 2026 Earnings Transcript

Medpace reported Q1 2026 revenue of $706.6 million, up 26.5% year over year, with EBITDA rising 25.9% to $149.4 million and EPS at $4.28. However, bookings weakened as net new awards were $618.4 million, book-to-bill fell to 0.88, and backlog cancellations hit the highest level in over a year, pressuring visibility and pointing to no sequential revenue growth over the next six months. Management kept full-year revenue, EBITDA, net income, and EPS guidance unchanged, but flagged ongoing cancellation risk, lower RFP volume, and no near-term productivity benefit from AI.

Analysis

MEDP’s print is less about near-term revenue durability than about a subtle deterioration in forward quality: the company is still converting a large installed backlog, but the funnel feeding that backlog is becoming more volatile. When cancellations rise while gross awards are also soft, the business shifts from a compounding story to a timing story, and timing stories are what multiple compression is made of. The key second-order effect is that even if current-year revenue is protected, the market will start discounting the 2027–2028 pipeline earlier than management is willing to quantify.

The market is probably underestimating how much of MEDP’s premium valuation has been supported by perceived booking visibility rather than current margin profile. The margin floor looks intact, but that is not enough if backlog coverage beyond 12 months keeps eroding; CRO multiples tend to de-rate first on visibility, not earnings. Elevated pass-through mix also muddies the signal: it props up top-line growth now but implies less true underlying service demand, so a future step-down there could expose a slower organic core than headline revenue suggests.

The contrarian point is that management’s caution may actually be the most bullish element here: they are explicitly signaling no sequential revenue growth over the next six months while still hiring and keeping guidance unchanged. That usually means either they see enough already-authorized work to bridge the year or they are intentionally setting up an easier second-half compare. The inflection to watch is not book-to-bill alone, but whether cancellations normalize faster than new award quality improves; if that happens, the stock can re-rate quickly because sentiment is already leaning defensive.

Competitive dynamics favor larger diversified CROs and potentially lower-quality peers that can win on price if MEDP is selectively pulling back from risky awards. Biopharma M&A is a structural headwind for MEDP specifically because acquired programs often migrate away from incumbent specialty providers; that should be a quiet beneficiary for more diversified service models, not for pure-play high-touch CROs. AI is not a near-term offset — if anything, it is capex/opex inflation before productivity — so any sell-side narrative assuming margin expansion from automation over the next 12–24 months is premature.

Key Decisions for Investors

• Short MEDP on rallies into strength over the next 2-6 weeks; thesis is multiple compression from deteriorating backlog quality, with a cleaner entry if the stock re-tests post-earnings support and fails to reclaim it.
• Pair trade: long IQV / short MEDP for 3-6 months; IQV has more diversified demand and less single-name cancellation sensitivity, while MEDP’s premium multiple is most exposed to visibility disappointment.
• If already long MEDP, buy protective puts 3-6 months out rather than selling outright; the main risk is not a revenue miss this quarter but another quarter of weak bookings that forces the market to discount 2027 growth earlier.
• Watch for a reversal signal only if net bookings re-accelerate above revenue for 1-2 consecutive quarters; absent that, treat guidance confirmation as a dead-cat bounce catalyst, not a trend change.
• For event-driven traders, use a call spread overwrite against existing longs: upside can persist if cancellations normalize, but the skew is poor because the downside is tied to de-rating, not just an earnings miss.